Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. - Wikidata - awgldk - TriplyDB

Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.

Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.

http://www.wikidata.org/entity/Q45388033

about

The emerging role of ofatumumab in the treatment of chronic lymphocytic leukemia Prevention of Hepatitis B reactivation in the setting of immunosuppression KASL clinical practice guidelines: management of chronic hepatitis B Critical appraisal of rituximab in the maintenance treatment of advanced follicular lymphoma Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations Hepatitis B virus reactivation with a rituximab-containing regimen Antiviral prophylaxis in patients with solid tumours and haematological malignancies--update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO)Hepatitis B virus reactivation with rituximab-containing regimen Management of patients with hepatitis B who require immunosuppressive therapy Occult hepatitis B virus infection Clinical impact of occult hepatitis B virus infection in immunosuppressed patients Molecular mechanisms underlying occult hepatitis B virus infection.Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy Update on occult hepatitis B virus infection Hepatitis B Reactivation During Immunosuppressive Therapy or Cancer Chemotherapy, Management, and Prevention: A Comprehensive Review-Screened Treatment of rheumatic diseases and hepatitis B virus coinfection Reactivation of hepatitis B virus in HBsAg-negative patients with hepatocellular carcinoma Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.Prevention of hepatitis B virus reactivation under rituximab therapy.Hematologic safety of breast cancer chemotherapies in patients with hepatitis B or C virus infection.Long-term follow-up of children with refractory immune thrombocytopenia treated with rituximab.Hepatitis C virus screening in patients with cancer receiving chemotherapy.Effect of Antiviral Prophylaxis Strategy for Chemotherapy-Associated Hepatitis B Reactivation in Non-Hodgkin's Lymphoma Patients with Hepatitis B Virus Infection: A Retrospective Cohort Study.A case of anti-GBM glomerulonephritis superimposed on HBV-associated membranous nephropathy Hepatitis C virus reactivation in cancer patients in the era of targeted therapies.Hepatitis B-related events in autologous hematopoietic stem cell transplantation recipients.Natural history of chronic hepatitis B: phases in a complex relationship.Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study.Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: molecular mechanisms and clinical significance.The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor.Hepatitis B virus management to prevent reactivation after chemotherapy: a review.Chemotherapy-related reactivation of hepatitis B infection: updates in 2013.Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients.Adrenalectomy to treat reactivated chronic hepatitis B infection in a patient with a steroid-secreting adrenal tumour.Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports Current hepatitis B screening practices and clinical experience of reactivation in patients undergoing chemotherapy for solid tumors: a nationwide survey of medical oncologists.Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center.Risk factors for hepatitis B virus reactivation after conformal radiotherapy in patients with hepatocellular carcinoma.Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma.Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs.

P2860

Q24617708-DFDD75FD-F249-4C8F-9F6E-9A2DF8DF69B8 Q26747023-A154512C-FDBA-42FA-9430-996CF963F3A9 Q26752475-0BC80AF3-0DE0-413D-86C9-4626C3604F52 Q26775837-BB946C1E-5383-427D-9ABA-B40FD464D896 Q26784247-A99E556E-9FD7-44AD-BE48-11F9D6F5751D Q26785963-799AFA69-1034-4B80-A72B-AA877599E792 Q26801716-E1ED0195-D5FF-4329-8A0F-DCDC2AA09490 Q26830484-10E3BDE8-187C-4EF2-89B4-125C5E19C33F Q26853490-FF216709-78A1-49C7-A0A1-B46C9F62197E Q27004224-0228A5D3-9681-4438-B449-B209AE94D783 Q27006996-D689F359-BB6D-4DE3-AC1F-CDA32CB2EA95 Q27686923-7FEEC644-EFDC-4308-ABA5-6554E8D0D87E Q28070090-97525BD2-B6D0-4AAC-957C-257FDE6FBDC7 Q28070317-99E7C040-E745-4496-BB63-71F2AD3E6471 Q28076703-C6614E0E-93F7-474D-AD66-CD89A7E8C285 Q28084305-6EABB671-2875-4BFA-88CD-D434E84AD63B Q28546530-FBCC974F-35AF-45C1-836E-781C2E911190 Q30391932-E3314275-6127-423C-8B6C-CD7C4EBD7F7A Q33390799-355C215C-CFA5-4503-BA93-D84A96318251 Q33400777-3F382F1A-0103-4E6F-AF30-0FA266B08BD9 Q33413781-96D76D97-5717-4430-8EA2-575575E5D7B6 Q33600085-3D301C9E-7C3F-4721-86C1-D6073DB893BB Q33619636-FC98604E-4D3C-4EDB-8000-D57A0D5E1608 Q33622153-E478377A-19B7-4976-A5A2-58E9F90BE7EF Q33735212-574373B7-476B-4E60-A97C-30F906D33257 Q33782078-C0891929-7F66-4C80-BD9A-CDE7E20FDD3E Q34036650-5A13CF2B-B3E4-440D-B1F3-7FAF51129B2F Q34106504-16A4F287-96D3-431C-8E37-41363B4629C4 Q34289969-FD544D8A-38E0-4EA5-8E80-E91CE40545BE Q34374056-706665C1-561E-413A-BF72-C3866614B4CD Q34397738-2B03DA03-00BD-4EBB-A0AF-AE24C8350184 Q34404991-59CEB6F8-8C4D-40FA-8A5B-BA2BC2EAB122 Q34413239-A81CC991-6A97-4510-8CC1-0E11D8049AE1 Q34705951-62D41819-51C4-4299-9681-620BE6274591 Q34854165-23070583-7D6D-4521-9141-1AE17BB0BE13 Q34974883-88E29797-EC72-43D7-948C-C40527ECF0CA Q35037621-0FF56336-6AD9-4810-97F5-BB16B1949679 Q35051831-C353634C-B69D-4D9A-A61C-E2BFD7D3D7FC Q35095916-8688D581-7635-48C5-9286-5031F75D0137 Q35237316-DE543EAF-6B41-4879-9C13-AF8948ECBED5

P2860

Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.

http://www.wikidata.org/entity/Q45388033

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

Hepatitis B virus reactivation ...... apy with or without rituximab.

@en

Hepatitis B virus reactivation ...... apy with or without rituximab.

@nl

type

label

Hepatitis B virus reactivation ...... apy with or without rituximab.

@en

Hepatitis B virus reactivation ...... apy with or without rituximab.

@nl

prefLabel

Hepatitis B virus reactivation ...... apy with or without rituximab.

@en

Hepatitis B virus reactivation ...... apy with or without rituximab.

@nl

P1433

Q45388033-DE65FB01-1FE8-4A50-9903-8B9219607F7E

P1476

Q45388033-EFB5D36E-7401-4F6F-807D-E1646B73296B

P2093

Q45388033-1E832EAE-1102-46D1-9EBE-5E5F674AEC3D

Q45388033-2920E3F3-9EE3-45A2-BC79-BF298A5A43AD

Q45388033-38D505FB-A481-41EA-BD82-AC2E803B56B4

Q45388033-566243DC-8B8C-4BD5-81A9-01B08F14182F

Q45388033-9B40F1C7-B8C9-4A71-B294-ED280BD74FC6

Q45388033-9C6DB3D2-F2F1-46C5-8005-7C100C520A5E

Q45388033-9E0E201C-DE4A-4494-9D80-70F430BFEC97

Q45388033-B11EDDB5-3A7F-4CE4-87CB-B44E64EF42DE

Q45388033-E3A9CF7B-D7C6-4961-979C-138F80E5A363

P304

Q45388033-829A8804-EC37-4D79-B9DC-F96682B76785

P31

Q45388033-9FBF9738-1CE2-4978-9022-79E7FE1934FE

P356

Q45388033-AC166162-9634-4CCE-9E27-03FFEC763584

P407

Q45388033-04A6295B-F36A-4C38-A10A-F4F286CCEE01

P433

Q45388033-60837918-4FDC-415C-978F-15E56F098F8D

P478

Q45388033-55750446-DBB8-4112-8DB0-C25940146DF8

P50

Q45388033-7C4C51F5-215A-4706-ACBB-E6F023A47888

Q45388033-8712EBAA-08BE-48B6-B868-66BC00EDDC1C

P577

Q45388033-72A9AAFC-CB75-4FA6-A6A7-7798D21D9159

P698

Q45388033-505C2865-439E-45C5-A8D6-DEF61E73E838

P356

JCO.2008.18.0182

P1433

Journal of Clinical Oncology

P1476

Hepatitis B virus reactivation ...... rapy with or without rituximab

@en

P2093

Edwin P Hui

http://www.w3.org/2001/XMLSchema#string

Frankie K F Mo

http://www.w3.org/2001/XMLSchema#string

Henry L Y Chan

http://www.w3.org/2001/XMLSchema#string

Kenny I K Lei

http://www.w3.org/2001/XMLSchema#string

Miu Ting Chu

http://www.w3.org/2001/XMLSchema#string

Nancy W Y Leung

http://www.w3.org/2001/XMLSchema#string

Paul K S Chan

http://www.w3.org/2001/XMLSchema#string

Tung C Chan

http://www.w3.org/2001/XMLSchema#string

Wai Y Lam

http://www.w3.org/2001/XMLSchema#string

P304

605-611

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2008.18.0182

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-12-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19075267

http://www.w3.org/2001/XMLSchema#string